Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features,risk factors,clinical and laboratory profile

Abstract

We report the experience from the Antiphospholipid Antibodies (aPL) Regional Consortium in northwest Italy, meant to support clinical research and foster collaboration among health professionals regarding the diagnosis and management of antiphospholipid syndrome (APS) patients. This cohort-study (APS Piedmont Cohort) was designed to register the clinical characteristics at inception and associated immunological manifestations at diagnosis (if any) of patients who strictly fulfilled the current criteria for APS, all recruited at the Piedmont and Valle d'Aosta regions.

Clinical and laboratory data from 217 APS patients (171 with vascular events, 33 with pregnancy morbidity and 13 with both), from 16 centres within the geographical area were collected. Venous thrombosis was recorded in 45.6% of patients, arterial thrombosis in 35%, small-vessel thrombosis in 1.12% and mixed arterial and venous thrombosis in the remaining 19.4% of the cases. Pregnancy morbidity included 19 patients with unexplained fetal death beyond the 10th week of pregnancy, 17 with premature birth before the 34th week and 10 with three or more unexplained spontaneous abortions before the 10th week of gestation. This consortium represents an instrument by which to audit clinical practice, to provide counselling to local centres and to sustain future basic and clinical APS research.

Keywords

antiphospholipid antibodies (aPL)antiphospholipid syndrome (APS)

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Cervera

Piette

Font

. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

Pierangeli

de Groot

Dlott

. Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010 ‘Criteria' aPL tests: report of a task force and preconference workshop at the 13th International. Lupus 2011; 20: 182–190.

Pengo

Tripodi

Reber

. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

Wilson

Gharavi

Koike

. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999; 42: 1309–1311.

Garcia-Carrasco

Galarza

Gomez-Ponce

. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus 2007; 16: 366–373.

Pengo

Ruffatti

Legnani

. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–242.

Pengo

Ruffatti

Legnani

. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibodies profile: a multicenter prospective study. Blood 2011; 118: 4714–4718.